PLUS1
0.4598
0.0083 (1.84%)
0.0083 (1.84%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.0121 | -2.61% | 0.4515 | 0.433 | 0.47 | 0.46 | 0.4636 | 17:52:56 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.455 | 0.4598 | 0.0048 | 1.04% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,570 | 11,533,813 | $ 0.451043 | $ 5,202,246 | 8,392,627 | 0.1027 - 4.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:59:44 | 50 | $ 0.4598 | USD |
Onconova Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 76.15M | 168.67M | 167.16M | $ 2.18M | $ - | -1.50 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 0.90% |
Onconova Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/02/2020 | 17:29 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 6/02/2020 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/21/2020 | 17:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/20/2020 | 09:20 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/20/2020 | 09:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/20/2020 | 09:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/19/2020 | 06:00 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.3969 | 0.523 | 0.38 | 0.4606517 | 14,771,814 | 0.0546 | 13.76% |
| 1 Month | 0.305 | 0.523 | 0.30 | 0.4061505 | 11,999,092 | 0.1465 | 48.03% |
| 3 Months | 0.30 | 0.523 | 0.273 | 0.3607982 | 7,767,203 | 0.1515 | 50.5% |
| 6 Months | 0.34 | 0.749 | 0.25 | 0.4184697 | 14,914,338 | 0.1115 | 32.79% |
| 1 Year | 3.25 | 4.00 | 0.1027 | 0.4031895 | 8,698,298 | -2.80 | -86.11% |
| 3 Years | 31.95 | 42.45 | 0.1027 | 1.47 | 3,322,047 | -31.50 | -98.59% |
| 5 Years | 42.6735 | 122.55 | 0.1027 | 2.49 | 2,067,235 | -42.22 | -98.94% |
Onconova Therapeutics Description
| Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways. |
